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ABSTRACT 15 
Mycobacterium tuberculosis (Mtb) infects one-third of the world’s population, and in 2013 16 
accounted for 1.5 million deaths. Fluoroquinolone antibacterials, which target DNA gyrase, are 17 
critical agents used to halt the progression from multidrug-resistant tuberculosis to extensively 18 
resistant disease; however, fluoroquinolone resistance is emerging and new ways to bypass 19 
resistance are required. To better explain known differences in fluoroquinolone action, the crystal 20 
structures of the wild-type Mtb DNA gyrase cleavage core and a fluoroquinolone-sensitized mutant 21 
were determined in complex with DNA and five fluoroquinolones. The structures, ranging from 2.4-22 
2.6 Å resolution, show that the intrinsically low susceptibility of Mtb to fluoroquinolones correlates 23 
with a reduction in contacts to the water-shell of an associated magnesium ion, which bridges 24 
fluoroquinolone-gyrase interactions. Surprisingly, the structural data revealed few differences in 25 
fluoroquinolone-enzyme contacts from drugs that have very different activities against Mtb. By 26 
contrast, a stability assay using purified components showed a clear relationship between ternary 27 
complex reversibility and inhibitory activities reported with cultured cells. Collectively, our data 28 
indicate that the stability of fluoroquinolone/DNA interactions is a major determinant of 29 
fluoroquinolone activity, and that moieties which have been appended to the C7 position of 30 
different quinolone scaffolds do not take advantage of specific contacts that might be made with the 31 
enzyme. These concepts point to new approaches for developing quinolone-class compounds that 32 
have increased potency against Mtb and the ability to overcome resistance.  33 
34 
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SIGNIFICANCE STATEMENT 35 
Although tuberculosis is a curable disease, its etiological agent, Mycobacterium tuberculosis (Mtb), 36 
remains a major human pathogen. Control of Mtb is hindered by multidrug-resistant strains. These 37 
are currently treated with second-line agents including fluoroquinolones such as moxifloxacin, which 38 
is one of a powerful three-drug regimen in trials against Mtb. Unfortunately, fluoroquinolone 39 
resistance is increasing, making improvements to quinolone efficacy clinically important. 40 
Fluoroquinolones act by forming complexes that poison Mtb. This study describes the first X-ray 41 
crystal structures of the Mtb gyrase cleavage core complexed with DNA and five fluoroquinolones. 42 
These comparative structures inform efforts to design new quinolone-class agents and establish that 43 
the low intrinsic susceptibility of Mtb to clinically-used fluoroquinolones is due to a paucity of 44 
specific gyrase-drug interactions. 45 
  46 
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\body 47 
INTRODUCTION 48 
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is one of the most 49 
important pathogens of humans, second only to the human immunodeficiency virus in the number 50 
of deaths caused annually (1). Mtb is estimated to latently infect one-third of the world’s population 51 
(2), thereby also creating a huge reservoir for future disease. Particularly problematic are cases of 52 
multidrug-resistant (MDR)-TB, which is defined as resistance to two primary anti-tuberculosis drugs, 53 
rifampicin and isoniazid. MDR-TB now represents 3.5 % of new TB cases; of these, 9 % are classified 54 
as extensively drug-resistant (XDR)-TB (1), which is defined as MDR-TB with additional resistance to 55 
any fluoroquinolone and one injectable second-line drug (3). TB isolates are also being recovered 56 
that are totally drug-resistant (3–5). Thus, controlling TB, in particular drug-resistant tuberculosis, is 57 
a major health problem.  58 
 59 
Fluoroquinolones are one of the most successful classes of drug against bacterial pathogens, 60 
accounting for 24 % of the $10 billion US antibiotic market (6). Fluoroquinolones are also currently 61 
receiving considerable attention in the treatment of TB, with two new C8-methoxy derivatives, 62 
moxifloxacin and gatifloxacin, currently under evaluation as promising first-line therapeutics (7–10). 63 
These compounds have been used to restrict the development of XDR-TB from MDR-TB; however, 64 
emerging resistance threatens both first-line and second-line use (11). The widespread testing of 65 
fluoroquinolones against tuberculosis has revealed considerable variation in efficacy of different 66 
drug variants against Mtb. For example, ciprofloxacin is only marginally active, and its early use with 67 
Mtb was halted in favor of ofloxacin and levofloxacin (7). These two agents are now proving to be 68 
less effective than moxifloxacin and gatifloxacin (7, 10); however, the newest two compounds also 69 
exhibit some non-ideality. For example, gatifloxacin can elicit side-effects such as hypo/hyper-70 
glycaemia (12), while moxifloxacin has potential cardiovascular risks (13). Although recent clinical 71 
trials that have included fluoroquinolones as part of an alternative drug-regimen have faltered (14), 72 
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there are prospects for other non-fluoroquinolone molecules to make an impact on the treatment of 73 
MDR- and XDR-TB (15, 16). Moreover, a promising recent trial, which uses moxifloxacin as part of a 74 
3-drug regimen together with pretomanid and pyrazinamide (MPaZ), reports superior bactericidal 75 
activity against TB and MDR-TB versus current regimens (17). These new data make it clear that new 76 
quinolone-class agents, which are also capable of circumventing known resistance mutations, might 77 
be useful therapeutic agents in the treatment of TB. 78 
 79 
Progress is presently being made toward developing new fluoroquinolone derivatives. For 80 
example, a methoxy group at fluoroquinolone position C8 (Fig. 1A) increases activity against 81 
mycobacteria, particularly resistant mutants (18–20). Indeed, moxifloxacin, along with a more active 82 
C8-methyl derivative, retain high inhibitory activity against purified Mtb gyrase even when the 83 
enzyme contains commonly acquired fluoroquinolone-resistance substitutions (see accompanying 84 
manuscript by Aldred et al). In another example, quinazolinediones (diones) have been shown to 85 
have an ability to bypass existing resistance within mycobacteria and other bacterial species (20–23). 86 
Thus, there still exist opportunities to design more effective quinolone-class molecules for treatment 87 
of TB.  88 
 89 
DNA gyrase is a heterotetrameric (GyrA2GyrB2) enzyme that transiently catalyzes double-strand 90 
(ds) DNA breaks as it negatively supercoils DNA. Fluoroquinolones prevent the re-sealing of the ds 91 
breaks that normally follows DNA strand passage (24), generating persistent, covalent enzyme-DNA 92 
adducts called cleaved complexes. Cleaved-complex formation, which is reversible, blocks bacterial 93 
growth; at elevated fluoroquinolone concentrations, release of DNA breaks from the complexes 94 
leads to chromosome fragmentation and cell death (25). Although numerous crystallographic studies 95 
have defined the primary binding site of fluoroquinolones against gyrase (and against topoisomerase 96 
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IV, a gyrase paralog) (26–29), there has been debate as to whether fluoroquinolones use a 97 
magnesium ion to bridge their interaction with the enzyme (27, 28). Resolving this question is 98 
important, as the intrinsic resistance of certain species of gyrase to quinolones (e.g., Mtb) has been 99 
proposed to result from natural sequence variation that leads to the loss of a magnesium-ion 100 
“bridge” formed between the drug and enzyme (30–32). At the same time, there currently exists no 101 
clear chemical explanation as to why certain fluoroquinolone derivatives act with different efficacies 102 
against Mtb gyrase.  103 
 104 
To better understand such questions, we carried out a structural and biochemical analysis of 105 
Mtb gyrase in the presence of a panel of four different, clinically-used fluoroquinolones 106 
(ciprofloxacin, levofloxacin, gatifloxacin and moxifloxacin) and one new fluoroquinolone derivative 107 
(C8-Me-moxifloxacin). X-ray crystallography revealed that Mtb gyrase indeed makes an intrinsically 108 
low number of interactions with a magnesium ion that accompanies fluoroquinolone binding, and 109 
that the introduction of a drug-sensitizing mutation (GyrA A90S) restores interactions seen in non-110 
resistant gyrase homologs. In vitro, we find that C8-Me-moxifloxacin and moxifloxacin are most 111 
effective at promoting cleaved complex formation and inhibiting DNA supercoiling by Mtb gyrase, 112 
followed by gatifloxacin, and then ciprofloxacin and levofloxacin; however, crystal structures of the 113 
DNA-binding-and-cleavage core of Mtb gyrase with both DNA and drug surprisingly failed to reveal 114 
any substantial differences in the contacts formed between the protein and different drugs. Further 115 
biochemical investigations using an assay that monitors the stability of pre-formed cleaved-116 
complexes largely corroborated the rank-order of inhibition seen in DNA cleavage experiments, and 117 
moreover resulted in drug efficacy trends that closely accord with clinical effectiveness. Collectively, 118 
our data explain why Mtb gyrase is naturally quinolone resistant and show that the relative activities 119 
of existing panels of anti-TB quinolone therapeutics are heavily influenced by base-stacking 120 
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interactions and have yet to take advantage of direct gyrase contacts to maximize therapeutic 121 
potential. 122 
123 
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RESULTS 124 
A C8-methyl derivative of moxifloxacin shows enhanced DNA cleavage with Mtb gyrase 125 
over clinically-used fluoroquinolones.  126 
Mtb is well known to have a low susceptibility to fluoroquinolones (33, 34). For example, the 127 
wild-type minimal inhibitory concentration (MIC) for ciprofloxacin and levofloxacin is 20- and 140- 128 
fold higher, respectively, with Mtb than with Escherichia coli (30). Part of this innately low 129 
susceptibility has been proposed to arise from a natural variation in the Quinolone-Resistance 130 
Determining Region (QRDR) of the GyrA subunit of gyrase that substitutes an alanine (Ala90 in Mtb) 131 
for what is typically a serine at the second amino acid of helix α4. As a serine, this amino acid has 132 
been seen in some instances to participate in a water/magnesium ion bridge that connects the 133 
enzyme (topoisomerase IV or gyrase) to the fluoroquinolone (28) (interestingly, while biochemical 134 
studies have substantiated the importance of this interaction (35–38), magnesium ion binding has 135 
not been observed crystallographically in all instances, leading to some debate as to its relevance 136 
(27, 28). Acquired resistance also centers in general around the helix α4 region, with 54 % of 654 FQ-137 
resistant isolates containing substitutions at residues 90, 91 and 94 of Mtb GyrA (11). 138 
 139 
To begin to define how Mtb gyrase responds in vitro to different, clinically-tested 140 
fluoroquinolones, we first purified full-length Mtb GyrA and GyrB, using the new consensus 675-141 
amino-acid form of GyrB (11, 39). To investigate Mtb’s innate fluoroquinolone insensitivity, an 142 
Ala90Ser (A90S) variant of Mtb GyrA, which has been predicted to aid in the formation of a 143 
water/magnesium ion bridge (31, 32), was also prepared. Wild-type (WT) Mtb GyrA and GyrAA90S 144 
proteins were combined with WT Mtb GyrB to form active heterotetrameric enzymes. These 145 
enzymes were then used to assess the fluoroquinolone-dependent generation of cleaved complexes 146 
(Fig. 1B), as monitored by the formation of linearized DNA from a starting supercoiled plasmid. In 147 
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this assay, levofloxacin produced the lowest amount of linear product, with ciprofloxacin, 148 
gatifloxacin and moxifloxacin showing between 2- and 4-fold higher cleavage activities at 10 µM 149 
drug (Fig. 1C left panel). By comparison, C8-Me-moxifloxacin produced 10-fold greater amounts of 150 
linearized DNA than levofloxacin at the same concentration (the level of activity for C8-Me-151 
moxifloxacin is actually an underestimate of the compound’s efficacy due to the formation of 152 
multiple cleaved complexes at drug concentrations >5 µM; the formation of multiple cleaved 153 
complexes on each DNA molecule degrades the linear product, artificially lowering the readout) (Fig. 154 
1B and C). When compared under similar conditions, the GyrAA90S form of Mtb gyrase consistently 155 
exhibited greater sensitivity to low fluoroquinolone concentrations than the WT enzyme (Fig. 1C 156 
right panel); the relative drug activity trends seen in cleaved-complex assays with the WT and 157 
GyrAA90S enzymes also were observed for the inhibition of ATP-dependent supercoiling (Fig. S1). 158 
Interestingly, a previous study testing each drug against Mtb in cell culture reported similar MIC 159 
values of 0.5 µg/ml for moxifloxacin, levofloxacin and ciprofloxacin, and a lower value of 0.1 µg/ml 160 
for gatifloxacin (31). This finding indicates that there is a disconnect in the rank-ordering drug of 161 
efficacy when using data obtained from MIC and from biochemical experiments. Nonetheless, the 162 
observed cleavage and supercoil-inhibition trends seen here are consistent with the observation that 163 
both ciprofloxacin and levofloxacin are less effective in the clinic than the fourth-generation 164 
fluoroquinolones gatifloxacin and moxifloxacin (7, 10).   165 
 166 
Crystallization of Mtb gyrase-DNA-fluoroquinolone complexes.  167 
To better understand structure-activity relationships that underlie the different activities of 168 
fluoroquinolones, both amongst themselves and against Mtb, we set out to solve the structure of 169 
Mtb gyrase bound to ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin, and C8-Me-moxifloxacin 170 
with DNA. Following a strategy that worked previously for Staphylococcus aureus gyrase (29), we 171 
linked the C-terminal region of GyrB (residues 426-675) and the N-terminal region of GyrA (residues 172 
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2-500) into a single polypeptide chain (termed GyrBA).  In parallel, a GyrAA90S variant of this construct 173 
was also prepared. The in vitro activity of the WT and mutant Mtb GyrBA fusions was confirmed by 174 
monitoring the cleavage of a supercoiled substrate in the presence of each of the five 175 
fluoroquinolones (Fig. S2A). Each drug induced DNA cleavage by the fusion protein (Fig. S2B left 176 
panel) and, as with full-length gyrase, cleavage was enhanced by the A90S substitution (Fig. S2B 177 
right panel). 178 
 179 
For crystallization, the fusion proteins were mixed with fluoroquinolone and a 24-mer 180 
dsDNA substrate, using an oligonucleotide sequence that had been previously crystallized with 181 
moxifloxacin and Acinetobacter baumannii topo IV (28). Following screening and refinement of 182 
crystallization conditions, we obtained the best data from co-crystals of the Mtb GyrBAWT fusion 183 
combined with both DNA and moxifloxacin, which diffracted to 2.4 Å. An initial solution was 184 
obtained for this complex by molecular replacement using a search model comprising only the 185 
protein and DNA from a previous, moxifloxacin-containing cleaved-complex structure (A. baumannii 186 
topo IV, PDB: 2XKK) (28). Having built and finalized this first structure, the protein and DNA from the 187 
Mtb gyrase model (without the drug) were subsequently used as a search model for all remaining 188 
cleaved-complex structures. In this manner, structures were obtained from 2.4 to 2.6 Å resolution 189 
for both the GyrBAWT and GyrBAA90S fusions in complex with moxifloxacin, C8-Me-moxifloxacin, 190 
gatifloxacin, and levofloxacin (Table S1). For ciprofloxacin, only the GyrBAA90S fusion formed crystals 191 
that diffracted to better than 3 Å resolution; the GyrBAWT crystal form showed consistently weak 192 
diffraction (>4 Å) and was not analyzed further. 193 
 194 
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Structure of Mtb DNA gyrase in complex with DNA and moxifloxacin.  195 
Inspection of the moxifloxacin-bound GyrBAWT structure shows that, as with other bacterial 196 
type IIA topoisomerase-DNA complexes (26–29), the Mtb gyrase cleavage core binds a single dsDNA 197 
within a channel that spans the dimer interface (Fig. 2A). The dsDNA is kinked at two points by the 198 
intercalation of Ile181 from GyrA into the minor groove, generating an upwardly curved duplex. Each 199 
strand is cleaved once, with the 5ʹ-phosphate of each cleaved strand covalently attached to one 200 
catalytic tyrosine (Tyr129) in each of the two GyrA regions (Fig. S3A). The presence of clear electron 201 
density allowed for the modeling of two moxifloxacin molecules, each wedged between the two 202 
ends of the cleaved DNA strands on both halves of the complex (Fig. 2B; Fig. S3A and B), in a drug-203 
binding pocket whose walls are formed by DNA base stacking. The orientation of moxifloxacin was 204 
immediately evident from electron density features, which also unequivocally showed that a 205 
magnesium ion was coordinated by the keto-acid group of each quinolone core (Fig. S3B). A GyrA 206 
dimerization interface (the “C-gate”), which is formed by a pair of coiled-coil arms extending from 207 
the principal DNA binding platform, was closed in the moxifloxacin-bound complex (Fig. 2C and D); 208 
this region has been seen in different conformational states in other type IIA topoisomerase 209 
structures (40, 41). A single magnesium ion and several associated waters are present in each of the 210 
two active sites at the so-called “B” (non-catalytic) position (42), coordinated by Glu459, Asp532, 211 
and Asp534 of GyrB (Fig. S3C). 212 
 213 
Comparison of the Mtb DNA- and fluoroquinolone-bound cleavage core with a previously 214 
determined apo structure of the N-terminal portion of Mtb GyrA (43) revealed two modest 215 
structural differences in the active site. First, a flexible loop from the apo structure (Ser178-Ile187) 216 
swings into a new position in the cleaved complex, forming two β-strands joined by a short turn (Fig. 217 
S4A). This β-sheet creates a portion of the DNA-binding surface and specifically presents GyrA-Ile181 218 
for intercalating into and bending DNA (Fig. S4A). Second, in its apo form, GyrA-Asp89 lies at the end 219 
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of a loop where it would form unfavorable contacts with an incoming fluoroquinolone (Fig. S4B); in 220 
the complex, Asp89 initiates helix α4 of GyrA, and the acidic side chain is rotated away from the 221 
keto-acid group of the fluoroquinolone to position Ala90 near the bound drug (Fig. S4B). The gyrase 222 
nucleolytic center thus undergoes multiple local movements that are likely important for allowing 223 
both enzymatic and drug-binding activities. 224 
 225 
Mtb gyrase naturally lacks reinforcing contacts to the water/magnesium ion bridge that 226 
are present in sensitized homologs. 227 
Examination of the region surrounding the keto-acid moiety of moxifloxacin bound to WT 228 
Mtb gyrase reveals a defined network of hydrogen bonds that link moxifloxacin, through a hydrated 229 
magnesium ion, to GyrA (Fig. 3B; Fig. S5A). In each model, two or three of the water molecules 230 
coordinating the drug-bound magnesium ions were clearly visible within the electron density (Fig. 231 
S5A and B) (additional waters were then placed to complete the octahedral coordination sphere 232 
commonly observed with magnesium ions (44) and within crystal structures of individual quinolones 233 
(45)). One notable, water-mediated magnesium-ion contact is with Asp94 of GyrA; this interaction 234 
likely accounts for why many substitutions at Asp94 lead to drug insensitivity in fluoroquinolone-235 
resistant laboratory and clinical strain isolates (11, 46) (see also accompanying manuscript by Aldred 236 
et al.). Comparison of the WT and A90S structures revealed that the hydroxyl from Ser90 also 237 
directly contacts magnesium ion-associated waters, as well as the quinolone keto-acid group directly 238 
(Fig. 3C; Fig. S5B). The absence of these contacts in the GyrBAWT structure accords with biochemical 239 
results showing that the natural presence of alanine at position 90 is at least partly responsible for 240 
the innately reduced susceptibility of the Mtb enzyme to fluoroquinolones, compared to homologs 241 
that retain a serine (or threonine, or asparagine) at this site (Fig. S5C) (30–32).  242 
 243 
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Diverse fluoroquinolones show few differences in binding interactions with the cleavage 244 
core of Mtb DNA gyrase.  245 
Having established the moxifloxacin-inhibited GyrBAWT and GyrBAA90S structures as a starting 246 
point for our investigations of fluoroquinolone mechanism, we next determined and examined the 247 
structures of the other fluoroquinolone-inhibited complexes. Globally, no large conformational 248 
changes were seen between the moxifloxacin-bound complex and all subsequent complexes. 249 
Simulated annealing omit maps (47) were generated for each of the ternary complex structures to 250 
confirm the correct fit of each fluoroquinolone with its associated magnesium ion and coordinating 251 
waters (Fig. 4). Identification of the fluoroquinolone N1 cyclopropyl and C8 group orientations was 252 
unequivocal (in the case of levofloxacin, the fused ring structure was clearly observed). The N1 253 
cyclopropyl and C8 methoxy groups of moxifloxacin and gatifloxacin adopt a trans configuration that 254 
extends out of the plane of the core ring structure, as predicted by energy minimization (48); the C8-255 
methyl of C8-Me-moxifloxacin remains in plane with the ring (Fig. 4). In comparison to the 256 
fluoroquinolone N1 and C8 groups, the C7 groups (which distinguish all of the drug variants 257 
examined here except moxifloxacin and C8-Me-moxifloxacin) were less well defined (Fig. 4). This 258 
observation suggests that these C7 moieties exhibit a degree of innate flexibility within cleaved-259 
complexes. The residues neighboring each C7 group – Arg482, Thr500, and Glu501 of GyrB – varied 260 
little in their relative positions, and made no specific contacts with the C7 group of any 261 
fluoroquinolone analyzed here. The unsubstituted C7 piperazinyl ring of ciprofloxacin resides > 4.2 Å 262 
from these neighboring residues, whereas the singly substituted rings in levofloxacin and gatifloxacin 263 
are within 3.4 Å and 3.8 Å of the same amino acids. Levofloxacin and gatifloxacin, together with both 264 
moxifloxacin compounds (which have larger C7 groups), thus are within the van der Waals contact 265 
radius of residues around the C7 ring, although these interactions appear generally loose and non-266 
specific (Fig. 4). 267 
 268 
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The corresponding Mtb structures were next aligned to the structures of type IIA 269 
topoisomerases from other bacterial species previously reported for cleaved complexes containing 270 
moxifloxacin (28), ciprofloxacin (29), and levofloxacin (27) (Figs. 4B, C and E, respectively). In each 271 
case, there did not appear to be any residues capable of making specific drug-protein contacts 272 
outside of the water/magnesium-ion bridge network. Interestingly, fluoroquinolone-resistant clinical 273 
isolates have been found with amino acid substitutions located around the C7 interaction locus of 274 
Mtb GyrB (Thr500 to Asn/Pro and Glu501 to Asp/Val) (11). Thus, GyrB residues in this region appear 275 
to form a favorable non-specific environment for hosting C7 groups that have been used in 276 
therapeutically-approved fluoroquinolones, rather than a tailored set of contacts that can interact 277 
with and potentially distinguish such drugs. 278 
 279 
Stability of Mtb gyrase-DNA-fluoroquinolone complexes correlates with activity.  280 
Altogether, the structural data on different Mtb GyrBA•DNA•drug complexes failed to show clear 281 
differences in the types of protein-drug interactions seen for the panel of five fluoroquinolones 282 
tested. While comparative MIC determinations have suggested that ciprofloxacin (0.5 µg/ml), 283 
levofloxacin (0.5 µg/ml) and moxifloxacin (0.5 µg/ml ) are equally effective against Mtb, and that this 284 
correlates approximately with supercoiling inhibition, this trend did not correlate well with 285 
previously-reported cleavage assays (31) or our own biochemical data (Figs. 1 and S1). We therefore 286 
elected to search for another measure of drug activity other than formation of cleavage complexes 287 
and supercoiling inhibition that might help explain this disconnect. 288 
 289 
Because cleaved complex formation is reversible (49), one can assess the relative stability of 290 
fluoroquinolone-poisoned gyrase•DNA adducts in solution (Fig. 5). In this approach, cleaved 291 
complexes are first generated with full-length gyrase, followed by their dilution into buffer 292 
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containing no drug (to lower the concentration of the compound). DNA resealing is then assessed by 293 
the loss of linear product over time using agarose gel electrophoresis (36). When starting at the 294 
same drug concentration (20 µM), ciprofloxacin provided the shortest half-life for cleaved-complex 295 
reversal (0.4 h), followed by levofloxacin (0.6 h), gatifloxacin (2.5 h), and then moxifloxacin (3.0 h) 296 
(Fig. 5A and C). Interestingly, under these initial assay conditions, it was not possible to measure the 297 
persistence of complexes formed with C8-Me-moxifloxacin because the DNA was heavily degraded 298 
by the robust ability of the compound to stimulate multiple cleavage events. We therefore lowered 299 
the initial inhibitor concentration 4-fold (to 5 µM), shortened the incubation step, and again 300 
compared the parent moxifloxacin with its C8-methyl derivative. Under these conditions, the half-301 
life for moxifloxacin was 0.9 h and 6.2 h for C8-Me-moxifloxacin (Fig. 5B and D). The GyrA A90S 302 
substitution further increased the stability of these complexes, raising the half-life of the 303 
moxifloxacin complex by 7-fold (to 7.0 h); under these conditions, the C8-Me-moxifloxacin 304 
complexes showed virtually no reversal. Thus, the observed order of fluoroquinolone activity seen 305 
within clinical studies (2, 7, 10), correlates most closely with the relative stabilities of the cleaved-306 
complexes formed by these agents. 307 
308 
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DISCUSSION 309 
We have determined the crystal structures of nine different fluoroquinolone•enzyme•DNA 310 
complexes for M. tuberculosis gyrase. Overall, the structures, which offer the highest resolution yet 311 
obtained for such complexes, are generally similar to those seen previously for other 312 
fluoroquinolone-inhibited type IIA topoisomerase structures (27–29): each GyrBA core binds and 313 
cleaves a single DNA duplex, and one fluoroquinolone stacks between each of the two base pairs 314 
that flank the sites of cleavage. In accord with gyrase and topo IV structures from Staphylococcus 315 
aureus and Acinetobacter baumannii, respectively (28, 29), a single water/magnesium-ion network 316 
can be seen to link each drug to a portion of helix α4 of GyrA, supporting biochemical studies 317 
implicating this feature as a key facet of fluoroquinolone/gyrase interactions. The structures 318 
corroborate previous predictions as to why Mtb has an innately low susceptibility to 319 
fluoroquinolones (30–32), showing that Ala90 of GyrA (which is a serine in most gyrase and topo IV 320 
orthologs) cannot participate in stabilizing this ion-bridging network (Fig. 3). The importance of the 321 
magnesium-ion interaction has been further demonstrated by studies of the Mtb fluoroquinolone-322 
resistance mutation GyrAA90V (see accompanying manuscript by Aldred et al.), which from our 323 
structures, would be predicted to sterically block formation of the water/magnesium bridge. Given 324 
that acquired fluoroquinolone resistance in clinical isolates of Mtb tends to cluster in amino acids 325 
participating in the water/magnesium bridge (11), our structures indicate that any change to this 326 
region likely will alter the overall shape complementarity of the drug pocket, potentially explaining 327 
the protective nature of other substitutions in the helix α4 region (such as GyrAG88C ) that have 328 
been observed in experiments using cultured cells (20).  329 
 330 
The present work is significant in that it assesses for the first time how five structurally 331 
different fluoroquinolones – ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin, and C8-Me-332 
moxifloxacin – all interact with a single topoisomerase target. Surprisingly, we could identify no 333 
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specific interactions between the different fluoroquinolones and gyrase that might account for 334 
established differences in their anti-bacterial activities in vivo (2, 7, 10). Structural comparisons 335 
indicate that this paucity of enzyme-drug interactions is characteristic of cleaved complexes 336 
involving other bacterial type IIA topoisomerases (Fig. 4). Despite this finding, the activities of the 337 
compounds can be biochemically rank-ordered with their relative in vivo efficacies by assessing the 338 
relative stabilities of cleaved-complexes in solution (C8-Me-moxifloxacin > moxifloxacin > 339 
gatifloxacin > levofloxacin > ciprofloxacin) (Fig. 5). This overall efficacy ranking is similar to that 340 
derived from assays that monitor cleaved-complex formation or supercoil formation, with the 341 
exception of levofloxacin and ciprofloxacin: in our hands, levofloxacin appeared more capable of 342 
stabilizing cleaved-complexes than ciprofloxacin (Fig. 5), but less capable of forming such complexes 343 
or inhibiting DNA supercoiling (Figs. 1 and S1). The more effective drugs such as C8-Me-moxifloxacin, 344 
moxifloxacin and gatifloxacin demonstrated the highest levels of supercoiling inhibition and DNA 345 
cleavage, implying that the catalytic rate of DNA cleavage is higher with these compounds. As 346 
enzyme inhibition is then maintained through increased cleaved complex stability, the catalytic rate 347 
for strand passage and re-sealing of dsDNA breaks would be reduced. Our data, however, show that 348 
this model requires refinement. Although levofloxacin showed lower levels of supercoiling inhibition 349 
in comparison to ciprofloxacin, this compound’s cleaved complexes were more stable. Nevertheless, 350 
cleaved-complex stability correlates well with in vivo efficacy and is likely to relate to the killing of 351 
Mtb cells; this hypothesis is supported by previous data showing how complex stability is a 352 
determining factor for the cytotoxicity of topoisomerase poisons within eukaryotic cells (50).  353 
The fact that drug structure affects the formation and reversal of cleaved complexes in a 354 
manner that cannot immediately be tied to observable differences in protein-fluoroquinolone 355 
interactions implies that some more subtle chemical feature of the compounds – such as electronic 356 
charge distribution or DNA base stacking – plays a key role in determining fluoroquinolone potency. 357 
Stacking interactions are likely to be defined by electron localization within the quinolone/dione 358 
core, which in turn may be influenced by ancillary C7 and C8 groups. The robust improvement of C8-359 
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Me-moxifloxacin activity compared to the C8-methoxy substituent in moxifloxacin alone highlights 360 
the power of fine-tuning the chemistry around the drug core. We hypothesize that the approximate 361 
7-fold increase in stability of the C8-Me-moxifloxacin cleavage complex over the moxifloxacin 362 
cleavage complex might be linked in part to an increase in movement by the C7-diazabicyclo ring 363 
within C8-Me-moxifloxacin. In moxifloxacin, the N1 cyclopropyl and C8 methoxy groups were 364 
predicted (48) and indeed crystallized in trans, with the methoxy positioned to potentially interact 365 
with the C7 ring (Fig. 4). Without this methoxy oxygen, the C7-diazabicyclo ring of C8-Me-366 
moxifloxacin may more freely rotate, and together with the absence of the oxygen atom, this may 367 
allow for new electronic charge distributions to form compared with moxifloxacin, resulting in 368 
altered base stacking and a more stable complex. Unfortunately for design efforts, stacking 369 
energetics are notoriously difficult to predict from structures. Stacking energetics can also be 370 
difficult to modulate through structure-based drug design approaches (51, 52), which struggle with 371 
the accurate accounting of factors such as flexibility or the entropy of drug binding (53). Further 372 
stability assays will be required to assess other substitutions at C8. 373 
 374 
The inability of different C7 substituents from the panel of fluoroquinolones tested here to 375 
make specific interactions with GyrB is notable. The C7 group of each tested fluoroquinolone is 376 
surrounded by the QRDR of GyrB (54) (Fig. 4). Amino acid substitutions within the QRDR can produce 377 
acquired resistance; however, of sequenced fluoroquinolone-resistant isolates, only 3 % carry 378 
substitutions within the QRDR of GyrB compared with 64 % within the QRDR of GyrA (11). In Mtb, 379 
GyrB resistance substitutions include Asn499Lys/Thr, Thr500Asn/Pro, and Glu501Asp/Val (11). None 380 
of these residues in GyrB are sufficiently close to form specific contacts with even the largest C7 381 
group tested (moxifloxacin) (Fig. 4). Instead, the structural data indicate that the QRDR of GyrB 382 
provides a complementary van der Waals surface that can favorably accommodate fairly large 383 
moieties and, together with a solvent exposed region above the C7 groups, that can allow for a 384 
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degree of conformational freedom for groups localized to this region. Much attention has already 385 
been paid to modifying C7 ring groups, with clear success (22, 48, 55); it seems likely that these 386 
improvements could be further capitalized upon by using longer linkers at the C7 position and 387 
allowing substituents to reach and contact side chains of amino acids such as Arg482, Thr500, or 388 
Glu501 in a more specific manner. In such an approach, it might be possible to pin a fluoroquinolone 389 
in the gyrase drug-binding pocket, using a water/magnesium-ion bridge from GyrA to anchor the 390 
keto-acid group at one end of the drug and specific contacts from GyrB to C7 features at the other; 391 
indeed, crosslinks can be formed between the C7 end of ciprofloxacin and GyrB-Glu466 of E. coli 392 
gyrase (equivalent to Mtb GyrB-Glu501) (49). This feature may be important for designing not only 393 
more active fluoroquinolones, but also more active quinazolinediones (56).  394 
 395 
The fluoroquinolone scaffold remains an important starting point for new antibiotics (57–396 
59). Indeed, both moxifloxacin (and in particular a new C8-Me-moxifloxacin derivative) retain high 397 
inhibitory activity in cell-free assays that employ Mtb gyrase with commonly acquired 398 
fluoroquinolone resistance substitutions (see accompanying manuscript by Aldred et al.). 399 
Moxifloxacin has also been shown to maintain efficacy against acquired fluoroquinolone resistance 400 
in a murine infection model of XDR strains (60). Data presented here indicate that fluoroquinolone 401 
development should aim not just for increasing specific drug/enzyme interactions, but also for 402 
integrating these efforts with investigations of the effects of drug variants on the stability of cleaved 403 
complexes; one such approach would be to combine structure-based drug design with structure-404 
activity relationship studies and cleaved-complex reversal assays. A challenge to such efforts will be 405 
to avoid the sole use of MIC as a means to score compound efficacy, and instead focus on cell killing, 406 
which mitigates resistance (61). A second will be to augment the anti-gyrase and anti-bacterial 407 
potency of new compounds while mitigating non-specific DNA intercalation and crossover against 408 
the human gyrase homologs, topo IIα and topo IIβ. 409 
410 
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MATERIALS AND METHODS 411 
Reagents. Ciprofloxacin-HCl salt, levofloxacin and moxifloxacin were obtained from Sigma-Aldrich. 412 
Gatifloxacin was obtained from Toronto Research Chemicals Inc. C8-Me-moxifloxacin was 413 
synthesized as described previously (37). Ciprofloxacin-HCl was dissolved in water; levofloxacin, 414 
moxifloxacin and C8-Me-moxifloxacin were all dissolved in DMSO; gatifloxacin was dissolved in HCl-415 
acidified DMSO (pH ~6) to 8 mM. With the exception of gatifloxacin, all drug solutions were 416 
dissolved to 20 mM and all final solutions were stored at -80 °C during experimentation. 417 
 418 
Preparation of plasmid DNA substrates. Negatively supercoiled pSG483 (2927 bp), a pBlueScript II 419 
SK+ (Agilent) derivative containing a BbvCI site, was prepared from E. coli XL-1 blue cells (Agilent) 420 
using a maxiprep kit (Macherey-Nagel). Relaxed pSG483 DNA was prepared by nicking the negatively 421 
supercoiled substrate with Nb.BbvCI (NEB), ligating with T4 DNA ligase (NEB), and purifying by 422 
ethanol precipitation. 423 
 424 
DNA assays. Full details of DNA supercoiling and DNA cleavage assays can be found in SI Materials 425 
and Methods. The stability assays were performed as follows, using a protocol adapted from 426 
previous examples (35, 62) (see also accompanying manuscript by Aldred et al.). Initial reaction 427 
mixtures were set up as per the DNA cleavage assays, except each 20 µL reaction contained 1 µM of 428 
gyrase heterotetramers and 100 nM of negatively supercoiled pSG483. In one set of reactions, 429 
ciprofloxacin, levofloxacin, gatifloxacin, and moxifloxacin were present at 20 µM; in a second set, C8-430 
Me-moxifloxacin and moxifloxacin were used at 5 µM. The first (high drug concentration) set was 431 
incubated at 37 °C for 1 h, whereas the second (low concentration) set was incubated for 30 min. 432 
After incubation, 1 µL of the reaction was taken as a “pre-dilution” sample and quenched with 433 
stopping buffer. Reactions were then diluted 20-fold by addition of 380 µL pre-warmed reaction 434 
buffer. 20 µL samples were taken at time points up to 7 h post-dilution, with the first sample taken 435 
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immediately after dilution (approximately 5-10 s) to represent the zero-hour time point. Samples 436 
were added directly to stopping buffer, and they were processed and analyzed as per the DNA 437 
supercoiling assays. Stability was measured by determining the loss of linear product over time 438 
compared to 100 % linear product set by the zero-hour time point. Gel images were analyzed using 439 
ImageJ (63), and data were plotted using Prism (GraphPad Software). Approximate half-lives were 440 
calculated using the non-linear regression “one phase decay” mode of Prism (GraphPad Software). 441 
 442 
Protein expression and cleavage complex structure determination. Full details concerning cloning, 443 
protein expression and purification, complex crystallization, X-ray data collection and structure 444 
determination can be found in SI Materials and Methods. 445 
446 
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FIGURE LEGENDS 719 
Figure 1. DNA cleavage by Mtb gyrase induced by fluoroquinolones. A Fluoroquinolones tested in 720 
this study. The constant quinolone core of each drug is highlighted in orange, numbered as shown 721 
around C8-Me-moxifloxacin. B DNA cleavage assays with full-length Mtb gyrase, using wild type (WT 722 
– upper gels) and a GyrA A90S (lower gels) sensitizing mutant. Each fluoroquinolone is titrated 723 
against a constant amount of protein (125 nM) and supercoiled (SC) plasmid DNA substrate (12.5 724 
nM). The “no protein” control shows the supercoiled substrate DNA, along with a nicked (N) and 725 
linear (L) control lanes. Each gel is representative of triplicate data. C Graphical analysis of data in B. 726 
The relative amount of DNA cleavage is plotted as an increase in linear product (obtained by 727 
densitometry) compared to the zero drug control as a function of drug concentration. Left panel – 728 
WT, right panel – A90S. Data points and error bars represent the mean and standard deviation of 729 
triplicate data, respectively. 730 
 731 
Figure 2. Structure of the Mtb GyrBA core in complex with DNA and moxifloxacin at 2.4 Å. A The Mtb 732 
GyrBA fusion comprises GyrB amino acids 426-675 and GyrA amino acids 2-500. Protein is shown as 733 
a surface with one fusion polypeptide in two shades of pink and the second in two shades of blue; 734 
darker sections indicate GyrB. DNA is shown in orange, with moxifloxacin as green spheres and 735 
magnesium ions in yellow spheres. B, C and D Orthogonal views of the complex in cartoon 736 
representation with transparent surfaces, related by indicated rotations. 737 
 738 
Figure 3. Mtb possesses a naturally-altered hydrogen bond network to the water/magnesium ion 739 
bridge. A View of the WT Mtb GyrBA active site (colored as Figure 2) with bound moxifloxacin (green 740 
sticks) and its associated water/magnesium ion ligand (red/yellow spheres). A single active site 741 
magnesium ion (lower yellow sphere) also can be seen, and is coordinated by E459, D532 and D534. 742 
The covalent Y129 phosphotyrosine linkage is shown as blue sticks. See Supplementary Figure 3 for 743 
29 
 
representative electron density. B Close-up of moxifloxacin bound to WT Mtb gyrase, through a 744 
bridging magnesium ion, coordinating waters, and adjacent DNA bases. C Close-up of moxifloxacin 745 
bound to A90S Mtb gyrase, showing the increased support of the hydrogen-bonding network by the 746 
additional A90S hydroxyl (olive).  747 
 748 
Figure 4. Comparison of fluoroquinolone-gyrase interactions. Mtb gyrase is colored as per Figure 2. 749 
Drugs are shown as green sticks, magnesium ions as yellow spheres and waters as red spheres. Both 750 
the bridging magnesium ion and the more distant active site magnesium ion are visible. Simulated 751 
annealing Fo-Fc omit maps were generated and are shown for each drug with accompanying 752 
magnesium and waters, contoured to 2.8σ. A C8-Me-moxifloxacin bound to WT Mtb gyrase. Mtb 753 
residues that interact with the fluoroquinolones are labeled and shown in each subsequent panel. 754 
Residues making van der Waals contacts with the C7 group are marked with an asterisk. B 755 
Moxifloxacin bound to WT Mtb gyrase. Also shown is a superposition of moxifloxacin in complex 756 
with A. baumannii topo IV (28) (PDB: 2XKK, light orange). C Ciprofloxacin bound to A90S Mtb gyrase, 757 
together with a superposition of ciprofloxacin in complex with S. aureus gyrase (29) (PDB: 2XCT, 758 
yellow). D Gatifloxacin bound to WT Mtb gyrase. E Levofloxacin with WT Mtb gyrase and a 759 
superposition of levofloxacin in complex with S. pneumoniae topo IV (27) (PDB: 3K9F, olive). 760 
 761 
Figure 5. Stability of full-length Mtb gyrase-fluoroquinolone-DNA cleavage complexes. A and B Time-762 
courses of linear product loss following dilution of cleavage complexes. “Pre” indicates the DNA 763 
content of the reaction prior to dilution. The zero time-point immediately follows dilution. Assay 764 
conditions were varied between A and B to allow for the increased cleavage activity of C8-Me-765 
moxifloxacin. Moxifloxacin was used in both sets of assays as a comparison. Gels are representative 766 
of triplicate data. C and D, graphical analysis of data in A and B, respectively. The level of linear 767 
product (obtained by densitometry) is normalized to the zero time-point and plotted as a function of 768 
30 
 
time. Data points and error bars represent the mean and standard deviation of triplicate data, 769 
respectively. 770 
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SUPPLEMENTARY MATERIALS AND METHODS 6 
Cloning. The coding regions for residues 2-675 of GyrB (11, 39) and 2-838 of GyrA from M. 7 
tuberculosis were amplified from genomic DNA (American Type Culture Collection strain H37Rv) and 8 
individually cloned into a pET-28b derivative containing an N-terminal, tobacco etch virus (TEV) 9 
protease-cleavable hexahistidine tag. A fusion of GyrB residues 426-675 and GyrA residues 2-500 10 
was formed and cloned simultaneously into a pET-28b derivative containing an N-terminal, TEV 11 
protease-cleavable hexahistidine and maltose binding protein tag, using SLIC (64); following TEV 12 
protease cleavage, the final protein is left with an extra SNA- sequence at its N-terminus. As part of 13 
the cloning procedure for SLIC, the fusions also contained an additional -IGSG sequence at the C-14 
terminus. Mutant vectors were generated by QuikChange (Agilent). 15 
16 
Protein expression and purification. The full-length and fusion proteins were treated similarly, 17 
except for an additional ion exchange step for the fusions. Protein was over-expressed in E. coli 18 
strain Rosetta 2 pLysS (EMD Millipore) by growing cells at 30 °C until early log phase, and then 19 
inducing with 1 mM isopropyl-β-D-thiogalactopyranoside for 3 hr. Cells were harvested by 20 
centrifugation and resuspended in buffer A500 (20 mM Tris-HCl pH 7.9, 500 mM NaCl, 5 mM 21 
imidazole pH 8.0 and 10 % glycerol with protease inhibitors (1 µg/ml pepstatin A, 1 µg/ml leupeptin, 22 
1 mM PMSF)), then frozen dropwise in liquid nitrogen for storage at -80 ˚C. 23 
1 
 24 
 For protein purification, cells were first thawed, sonicated and centrifuged (17,000 x g, 4 °C). 25 
The clarified lysate was next passed over a HisTrap HP column (GE Healthcare) and washed for ten 26 
column volumes with buffer A500. At this point, the two procedures diverge for full-length and 27 
fusion proteins. Full-length proteins were eluted with buffer B500 (20 mM Tris-HCl pH 7.9, 500 mM 28 
NaCl, 250 mM imidazole and 10 % glycerol with protease inhibitors), then concentrated and 29 
exchanged into buffer A500 overnight at 4 °C in the presence of His-tagged TEV protease. The fusion 30 
proteins bound to the initial HisTrap column were washed for a further 5 column volumes with A100 31 
(20 mM Tris-HCl pH 7.9, 100 mM NaCl, 5 mM imidazole pH 8.0 and 10 % glycerol with protease 32 
inhibitors), before elution directly onto a HiTrap Q HP column (GE Healthcare; pre-equilibrated in 33 
A100) using B100 (20 mM Tris-HCl pH 7.9, 100 mM NaCl, 250 mM imidazole and 10 % glycerol with 34 
protease inhibitors). The Q columns were transferred to an Äkta Explorer (GE Healthcare) and 35 
washed with 3 column volumes of A100, then the fusion proteins were eluted using a 50 ml gradient 36 
from 100 % A100 to 50 % buffer C (20 mM Tris-HCl pH 7.9, 1 M NaCl and 10 % glycerol with protease 37 
inhibitors). The protein peak eluted at approximately 32 % buffer C. Peak fractions were pooled, 38 
concentrated and incubated overnight at 4 °C with His-tagged TEV protease. 39 
 40 
 Following the TEV protease step, all protein mixtures were individually re-passaged over a 41 
HisTrap HP column in A500, and the flow-through was collected, concentrated, and run over an S-42 
300 gel filtration column (GE Healthcare) in buffer D (50 mM Tris-HCl pH 7.9, 500 mM KCl and 10 % 43 
glycerol). Peak fractions were pooled, concentrated, and when required for biochemistry, diluted 44 
into a high-glycerol variant of buffer D, so that the final glycerol concentration reached 30 % prior to 45 
aliquotting and snap-freezing in liquid nitrogen for storage at -80 °C. For samples used for 46 
crystallography, this protein was dialyzed overnight into buffer E (20 mM Tris-HCl pH 7.9, 150 mM 47 
NaCl, 2.5 mM DTT) then quantified and stored on ice for immediate use. If flash-frozen in liquid N2, 48 
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crystallization samples would still form usable crystals over a course of approximately 2-4 weeks of 49 
storage. 50 
 51 
DNA supercoiling assays. The DNA gyrase holoenzyme was formed by incubating equimolar 52 
amounts of GyrB and GyrA (to a final heterotetramer concentration of 10 µm) on ice for 10 min. 53 
DNA gyrase was then serially diluted in two-fold steps using protein dilution buffer (50 mM Tris-HCl 54 
pH 7.5, 2 mM MgOAc, 1 mM DTT, 500 mM KOAc, 50 µg/ml BSA and 10% glycerol), down to 78 nM. A 55 
reaction master mixture was made containing four parts diluted enzyme, five parts 4x reaction 56 
buffer (40 mM Tris-HCl pH 7.5, 38.4 mM MgOAc, 4 mM DTT, 100 µg/ml BSA and 32 % glycerol) and 57 
one part of a 500 ng/µL solution of relaxed plasmid DNA. The master mixture was incubated on ice 58 
for 5 min. Drug titrations were prepared by mixing 2 µL of an appropriate drug dilution (or 2 µL of 59 
solvent for “zero drug” controls) with 1 µL of 20 mM ATP and 7 µL of dH2O. These 10-µL drug 60 
mixtures were then added to 10 µL aliquots of the full reaction mixture on ice, quickly transferred to 61 
37 °C, and incubated for 30 min. Final reaction conditions were: 15.6 nM heterotetramer, 12.5 nM 62 
relaxed pSG483, variable drug content (or solvent only), 1 mM ATP, 20 mM Tris pH 7.5, 10 mM 63 
MgOAc, 1.2 mM DTT, 100 mM KOAc, 35 µg/mL BSA and 10 % glycerol. Following incubation, the 64 
reactions were first quenched with 2 µL of stopping buffer (5 % SDS, 125 mM EDTA), followed by 65 
adding 1 µL of 12 mg/ml proteinase K and a further incubation at 37 °C for 30 min. Samples were 66 
stored on ice until immediately prior to gel loading, whereupon a 6x agarose gel loading dye was 67 
added and the samples were warmed to 37 °C for 5 min. Samples were separated by electrophoresis 68 
in 1.4 % (w/v) TAE agarose gels (50 mM Tris-HCl pH 7.9, 40 mM NaOAc and 1 mM EDTA pH 8.0 69 
running buffer), for 6-15 h at 2-2.5 V/cm. To visualize the DNA, gels were post-stained with 0.5 70 
µg/mL ethidium bromide in TAE buffer for 30 min, de-stained in TAE buffer for a further 30 min, and 71 
exposed to UV illumination.  72 
 73 
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DNA cleavage assays. DNA cleavage assay were performed largely as per supercoiling assays, with 74 
some adjustments: the final concentrations of heterotetramer and fusion homodimer were 125 nM 75 
and 250 nM (respectively), negatively-supercoiled pSG483 was used as the substrate, and no ATP 76 
was included in the reaction. 77 
78 
Crystallization. The DNA sequence used for crystallization was based upon oligomers that had 79 
previously been successfully crystallized by Wohlkonig et al. (28). Complementary, non-palindromic 80 
24-nucleotide oligonucleotides with sequences 5ʹ-GGTCATGAATGACTATGCACGTAA-3ʹ and 5ʹ-81 
TTACGTGCATAGTCATTCATGACC-3ʹ were purchased from Integrated DNA Technologies, using the 82 
standard purification available. For annealing, oligos, were mixed 1:1 (each at 1.5 mM starting 83 
concentration) in water and heated to 95 °C for 5 min in a PCR machine, followed by step decreases 84 
of 1 °C per min, to an end-point of 12 °C. 85 
86 
 Covalent cleaved complexes were formed by scaling the following 10-µL mixture as 87 
appropriate for the number of trays being set. The following reagents were combined in order: 8.3 88 
µL of 6.5 mg/ml GyrBA (in buffer E), 0.4 µL of 100 mM MgCl2, 0.5 µL of 1.5 mM annealed oligos and 89 
0.8 µL of 10 mM fluoroquinolone. For ciprofloxacin, which was dissolved in water rather than DMSO, 90 
an additional 0.8 µL of 100 % DMSO was added to the mixture per 10 µL. Once combined, the 91 
sample was incubated in a PCR machine at 37 °C for 30 min and then stored on ice until setting trays. 92 
Following screening, a single crystal condition was identified in which the resulting complexes 93 
formed small showers of crystals. This condition was then refined, producing very thin (<10 µm) 94 
planar crystals. 95 
96 
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 Droplets used to grow data collection-quality crystals were set using a Mosquito robot (TTP 97 
Labtech). Hanging drops containing 450 nL complex plus 450 nL reservoir solution were set in 96-98 
well format, using 50-µL reservoirs. A small matrix of 12 crystallization conditions, repeated 8 times 99 
throughout the 96-well tray, was used to alleviate batch-to-batch and across-plate variation. The 100 
condition matrix used 100 mM Tris-HCl at a varying pH of 7.0, 7.5, 8.0 or 8.5, against 13, 14 or 15 % 101 
PEG 4000, with constant 200 mM MgCl2 and 6.25 % PEG 400. 102 
 103 
 Crystals that formed in these conditions varied widely, from showers to large plates, 104 
depending on the protein batch and day. Trays were screened for the larger, planar crystals, which 105 
could measure up to 200 µm by 300 µm in surface area, crystals never grew to greater than 10 µm in 106 
thickness. Crystals also occasionally grew in clusters that required careful teasing apart during 107 
harvesting. To harvest, 20 µL of reservoir was added to 20 µL of cryo buffer (25 mM Tris-HCl pH 7.9, 108 
187.5 mM NaCl, 3.125 mM DTT and 80 % glycerol) and mixed quickly by vortexing; 1 µL of this 109 
solution then was added to the 900-nl drop. After addition of cryo buffer, crystals were immediately 110 
extracted using a nylon loop and flash-frozen in liquid N2. 111 
 112 
Data collection and structure determination. Initial crystal screening to find suitable crystallization 113 
conditions was performed at beamlines 8.3.1 at the Advanced Light Source (Lawrence Berkeley 114 
National Laboratory) and X25 at the National Synchrotron Light Source (Brookhaven National 115 
Laboratory). The diffraction quality varied greatly not only between crystals but also between 116 
different regions of a single crystal. To obtain full data sets with suitable merging statistics, it was 117 
necessary to use the microfocus and rastering technologies available at beamlines 23-ID-B and 24-118 
ID-C of the Advanced Photon Source (Argonne National Laboratories) to identify the site at which to 119 
collect data. Hundreds of crystals were screened in this fashion to obtain final data sets. 120 
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121 
 Diffraction data were processed with XDS (65, 66). AIMLESS from CCP4 (67) corroborated 122 
the space group as P21. Initial molecular replacement for the first structure – WT DNA gyrase with 123 
DNA and moxifloxacin – was performed using PHASER (68) within CCP4 (67). The search model was a 124 
modified version of PDB entry 2XKK (28), with all waters, drug molecules, metals and the 125 
phosphotyrosines removed. The obtained solution underwent rigid-body refinement using REFMAC 126 
from CCP4 (67). The density maps were examined in COOT (69), which revealed clear difference 127 
density of the correct planarity and shape for moxifloxacin. The model was built using COOT and 128 
iterative rounds of refinements in PHENIX (70), including the use of TLS parameters (71, 72). Because 129 
the DNA substrate was not palindromic, the dsDNA was modelled in both orientations at 50 % 130 
occupancy. All ligands were constructed using SMILES strings as input for eLBOW (70); prior to each 131 
refinement, the model was prepared using READYSET (70). All loops of the Mtb GyrBA fusion were 132 
resolved in the structure, with the exception of an initial 5 or 6 amino acid portion of GyrB that 133 
forms part of the linker to the missing ATPase domain, and the initial 13 amino acids of GyrA that 134 
were co-opted for use as a linker between GyrB and GyrA. The RMSDs between the Mtb GyrBA core 135 
and the equivalent regions of A. baumannii topo IV (28), S. aureus gyrase (29) and S. pneumoniae 136 
topo IV (27) are 1.34, 1.18 and 1.35, respectively. All waters, drug molecules, metals and 137 
phosphotyrosines were removed from the final WT-moxifloxacin-DNA structure, to produce the 138 
search model for subsequent molecular replacement experiments with all other datasets, which 139 
were performed using the PHASER-MR module of PHENIX (70). All final structures contain one 140 
cleavage complex in the asymmetric unit and these complexes are essentially C2 symmetric, having 141 
2-fold rotational symmetry. Simulated-annealing omit maps were generated by deleting the drug 142 
molecules along with associated magnesium ions and coordinating waters from each model, then 143 
running simulated annealing within PHENIX.REFINE (70). Output simulated-annealing maps were 144 
then converted using FFT within CCP4 (67). Figures of all subsequent models were generated using 145 
PYMOL (73). Alignment of GyrA homologs was generated using ClustalX2 (74). 146 
6 
SUPPLEMENTARY FIGURE LEGENDS 147 
Supplementary Figure 1. Inhibition of full-length Mtb gyrase by selected fluoroquinolones. A ATP-148 
dependent DNA supercoiling by Mtb gyrase, comparing WT (upper gels) and the GyrA A90S mutant 149 
(lower gels). Each fluoroquinolone is titrated against a constant amount of protein (15.6 nM) and 150 
relaxed plasmid DNA substrate (12.5 nM). The “no protein” control shows the relaxed substrate 151 
DNA, along with a nicked (N) and linear (L) control lanes. The constant quinolone core of each drug is 152 
highlighted in orange. Each gel is representative of triplicate data. B Graphical analysis of data in A. 153 
Inhibition is measured by the reduction of supercoiled (SC) product (as measured by densitometry) 154 
in comparison to the zero drug control as a function of drug concentration. Left panel – WT, right 155 
panel – GyrA A90S mutant. Data points and error bars represent the mean and standard deviation of 156 
triplicate data, respectively. 157 
158 
Supplementary Figure 2. Mtb GyrBA core fusions cleave DNA in the presence of fluoroquinolones. A 159 
DNA cleavage assays with Mtb GyrBA, using WT (upper gels) and the GyrA A90S mutant (lower gels). 160 
Each fluoroquinolone is titrated against a constant amount of protein (250 nM) and supercoiled (SC) 161 
plasmid DNA substrate (12.5 nM). The “no protein” control shows the supercoiled substrate DNA, 162 
along with a nicked (N) and linear (L) control lanes. The constant quinolone core of each drug is 163 
highlighted in orange. Each gel is representative of triplicate data. B Graphical analysis of data in A. 164 
DNA cleavage is measured by the increase in linear product (as measured by densitometry) in 165 
comparison to the zero drug control as a function of drug concentration. Left panel – WT, right panel 166 
– GyrA A90S mutant. Data points and error bars represent the mean and standard deviation of 167 
triplicate data, respectively. 168 
169 
Supplementary Figure 3. Detailed structure and electron density of the wild-type Mtb GyrBA active 170 
site (moxifloxacin-DNA complex). The displayed 2Fo-Fc electron density maps have been contoured 171 
7 
to 1σ. A Moxifloxacin (green sticks), its associated magnesium ion (yellow sphere, upper) and 172 
supporting waters are wedged between two bases in the cleaved dsDNA (wheat sticks). The covalent 173 
linkage between the DNA and the catalytic tyrosine Y129 (blue sticks) is clearly visible. The single 174 
active site magnesium ion (at the non-catalytic “B” position (42)) can also be seen (bottom left). B 175 
Close-up side view of moxifloxacin, highlighting the unequivocal orientation and position of the drug 176 
molecule, together with the drug-bound magnesium atom. At lower contours, evidence can be seen 177 
for the solvent-exposed water residues that coordinate the outer edge of the ion. Residues T500 and 178 
R482 of GyrB make van der Waals contacts with the C7 ring. C Close-up view of the single active site 179 
magnesium atom, which also has stronger density for all coordinating water atoms, together with 180 
GyrB residues E459, D532 and D534. 181 
182 
Supplementary Figure 4. Overlay of the apo Mtb GyrA N-terminal domain structure (PDB: 3ILW) 183 
with the structure of Mtb GyrBA bound to DNA and moxifloxacin. A Detail of the DNA 184 
intercalation/bending site. Residues 179-188 of the apo GyrA form are displayed as a green cartoon 185 
and apo residues are designated with a prime symbol. The same region in the ternary 186 
GyrBA•DNA•moxifloxacin complex is shown as a salmon cartoon. The flexible loop containing I181ʹ 187 
forms a β-sheet upon binding DNA, which positions I181 to intercalate and kink the duplex. B Detail 188 
of the QRDR helix α4, colored as per A. D89ʹ in the apo form (purple dots) makes unfavorable 189 
contacts with the superposed moxifloxacin. In the presence of moxifloxacin (green spheres), D89 190 
moves and becomes the start of this helix, presenting A90 to the water/magnesium bridge network 191 
(magnesium ion, yellow sphere; waters, red spheres). 192 
193 
Supplementary Figure 5. Comparison of electron density around the water/magnesium bridge. The 194 
displayed 2Fo-Fc electron density maps have been contoured to 1σ. A WT Mtb GyrBA in complex 195 
with moxifloxacin (green sticks), bound to GyrA via a magnesium ion (yellow sphere) and its 196 
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supporting waters (red spheres). B A90S Mtb GyrBA in complex with moxifloxacin. In comparison to 197 
WT, there is additional electron density linking A90S (olive) to the coordinating water network. C 198 
Alignment of the GyrA/ParC QRDRs from representative species. The positions of residues 90 and 94 199 
from Mtb are indicated. Mtb, Mycobacterium tuberculosis; Msmeg, Mycobacterium smegmatis; 200 
Ecoli, Escherichia coli; Abau, Acinetobacter baumannii; Saureus, Staphylococcus aureus subsp. 201 
aureus; Spneumoniae, Streptococcus pneumoniae; Kpneumoniae, Klebsiella pneumoniae; 202 
Styphimurium, Salmonella enterica subsp. enterica serovar typhimurium; Lpneumophila, Legionella 203 
pneumophila; Hpylori, Helicobacter pylori. Alignment generated using ClustalX2 (74).  204 
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Table S1. Data collection and structure refinement statistics. 
WT•Moxi-
floxacin 
A90S•Moxi
-floxacin 
A90S•Cipro
-floxacin 
WT•Gati-
floxacin 
A90S•Gati-
floxacin 
WT•Levo-
floxacin 
A90S•Levo-
floxacin 
WT•C8-
Me-moxi-
floxacin 
A90S•C8-
Me-moxi-
floxacin 
PDB ID 5BS8 5BTA 5BTC 5BTD 5BTF 5BTG 5BTI 5BTL 5BTN 
Beamline NE-CAT 24-
ID-C 
NE-CAT 24-
ID-C 
NE-CAT 24-
ID-C 
GM/CA@APS 
23-ID-B 
NE-CAT 24-
ID-C 
GM/CA@APS 
23-ID-B 
NE-CAT 24-
ID-C 
NE-CAT 24-
ID-C 
NE-CAT 24-
ID-C 
Wavelength (Å) 0.979 0.979 0.979 1.033 0.979 1.033 0.979 0.979 0.979 
Resolution range 
(Å) 
102.3  - 
2.399 
(2.485  - 
2.399) 
49.46  - 
2.55 (2.641  
- 2.55) 
47.7  - 2.55 
(2.641  - 
2.55) 
47.39  - 2.497 
(2.586  - 
2.497) 
49.78  - 
2.61 (2.703  
- 2.61) 
46.33  - 2.5 
(2.589  - 2.5) 
49.43  - 
2.501 
(2.591  - 
2.501) 
49.6  - 2.5 
(2.589  - 
2.5) 
49.65  - 2.5 
(2.589  - 
2.5) 
Space group P 21 P 21 P 21 P 21 P 21 P 21 P 21 P 21 P 21 
Unit cell 108.357 
83.07 
129.856 90 
109.33 90 
108.34 
83.205 
129.757 90 
108.55 90 
108.336 
82.976 
129.703 90 
109.06 90 
107.907 
83.158 
129.203 90 
108.65 90 
108.955 
84.019 
130.59 90 
108.87 90 
108.094 
82.989 
129.101 90 
108.76 90 
108.39 
83.28 
129.701 90 
108.73 90 
107.938 
83.047 
128.737 90 
108.88 90 
108.337 
82.914 
129.078 90 
108.78 90 
Total reflections 289862 
(26760) 
240848 
(23112) 
239725 
(23493) 
285133 
(27395) 
224023 
(21110) 
283502 
(27762) 
253631 
(24762) 
250735 
(22801) 
254270 
(23071) 
Unique reflections 83492 
(8068) 
69802 
(6803) 
70181 
(6996) 
75313 (7331) 66236 
(6366) 
74925 (7410) 74477 
(7351) 
73827 
(7213) 
74277 
(7283) 
Multiplicity 3.4 (3.3) 3.5 (3.4) 3.4 (3.4) 3.8 (3.7) 3.4 (3.3) 3.8 (3.7) 3.4 (3.4) 3.4 (3.2) 3.4 (3.2) 
Completeness (%) 97.68 
(93.22) 
97.47 
(95.53) 
98.56 
(98.73) 
99.66 (97.56) 97.16 
(93.62) 
99.70 (99.57) 98.14 
(97.27) 
98.66 
(97.11) 
98.73 
(97.59) 
Mean I/sigma(I) 10.66 
(0.99) 
6.62 (0.66) 8.98 (1.26) 10.36 (1.10) 6.65 (0.86) 8.93 (1.37) 8.92 (1.35) 8.38 (0.91) 8.95 (1.12) 
Wilson B-factor 53.37 58.05 50.75 45.59 58.72 40.69 47.9 49.46 47.74 
R-merge 0.08799 
(1.313) 
0.1621 
(1.927) 
0.1104 
(1.06) 
0.1365 (1.389) 0.1449 
(1.33) 
0.1391 (1.061) 0.1072 
(0.9755) 
0.1335 
(1.352) 
0.1287 
(1.228) 
R-meas 0.1043 0.1921 0.1311 0.1593 0.1726 0.1624 0.1274 0.1589 0.1529 
CC 1/2 0.989 
(0.52) 
0.991 
(0.259) 
0.995 
(0.599) 
0.993 (0.365) 0.991 
(0.367) 
0.991 (0.545) 0.995 
(0.562) 
0.993 
(0.408) 
0.993 
(0.463) 
CC* 0.997 
(0.827) 
0.998 
(0.641) 
0.999 
(0.866) 
0.998 (0.732) 0.998 
(0.733) 
0.998 (0.84) 0.999 
(0.848) 
0.998 
(0.761) 
0.998 
(0.796) 
R-work 0.1957 
(0.3807) 
0.2233 
(0.3858) 
0.2243 
(0.3937) 
0.2146 
(0.3620) 
0.2304 
(0.3906) 
0.2256 
(0.3469) 
0.2145 
(0.3550) 
0.2297 
(0.3963) 
0.2232 
(0.3654) 
R-free 0.2329 
(0.3910) 
0.2507 
(0.3855) 
0.2496 
(0.3857) 
0.2464 
(0.3821) 
0.2612 
(0.3945) 
0.2491 
(0.3659) 
0.2402 
(0.3754) 
0.2555 
(0.4016) 
0.2508 
(0.3916) 
Number of non-
hydrogen atoms 
13659 13459 13449 13463 13445 13439 13546 13467 13485 
macromolecules 13194 13180 13180 13194 13196 13194 13196 13194 13196 
ligands 62 62 52 58 58 56 56 60 60 
water 403 217 217 211 191 189 294 213 229 
Protein residues 1550 1550 1550 1550 1550 1550 1550 1550 1550 
RMS(bonds) 0.004 0.004 0.004 0.004 0.004 0.003 0.003 0.004 0.003 
RMS(angles) 0.68 0.75 0.69 0.74 0.70 0.69 0.71 0.68 0.69 
Ramachandran 
favored (%) 
96 96 96 96 97 97 96 97 96.6 
Ramachandran 
allowed (%) 
4.0 4.0 4.0 4.0 3.0 3.0 4.0 3.0 3.4 
Ramachandran 
outliers (%) 
0 0 0 0 0 0 0 0 0 
Clashscore 3.03 3.19 3.15 3.03 2.68 3.38 3.54 2.88 3.03 
Average B-factor 72 76.7 74.2 64.2 72.8 61.5 67 69.3 67.9 
macromolecules 72.6 76.9 74.5 64.6 73.3 61.9 67.1 69.5 68.1 
ligands 48.3 57 69.6 43.4 52.4 34.5 41.7 45 64.2 
solvent 54.7 68.7 57.7 47.2 45.8 43.7 69.5 64.9 55.4 
Fig. S1
Fig. S2
Fig. S3
Fig. S4
Fig. S5
